Abstract:
:Coronary artery disease and acute myocardial infarction still represent the leading cause of mortality in developed countries. Therefore, great efforts have been made in the last decades to improve reperfusion strategies and adjunctive antithrombotic therapies. In fact, despite optimal epicardial recanalisation, a large proportion of patients still experience impaired reperfusion and in-stent thrombosis. The adjunctive use of glycoprotein (GP) IIb-IIIa inhibitors may certainly contribute in the reduction of such complications, especially when administered in the early phase of infarction. In fact, in this phase a larger platelet composition of the thrombus and the presence of a larger amount of viable myocardium, as compared to a delayed phase, may increase the benefits from this therapy and counterbalance the potential higher risk of bleeding. A large body of evidence has been accumulated on the benefits from GP IIb-IIIa inhibitors in terms of prevention of stent thrombosis, and benefits in mortality, especially among high-risk patients and as upstream strategy. Therefore, based on current available data, GP IIb-IIIa inhibitors can be recommended as early as possible (upstream strategy) among high-risk patients, such as those with advanced Killip class or anterior myocardial infarction (MI), and those presenting within the first three hours. Even though it is not universally accepted, in our opinion this strategy should be implemented in a pre-hospital setting (in ambulance) or at first hospital admission (Emergency Room or Coronary Care Unit, irrespective of whether they are in the spoke or hub hospitals). Peri-procedural intracoronary administration of GP IIb-IIIa inhibitors has not provided additional benefits as compared to intravenous administration and therefore cannot be recommended. Even though the vast majority of trials have been conducted with abciximab, several meta-analyses comparing small molecules (mainly high-dose tirofiban rather than eptifibatide) versus abciximab showed similar angiographic and clinical results between the molecules. Several recent investigations and meta-analyses have documented the higher risk of stent thrombosis associated with bivalirudin as compared to unfractionated heparin (UFH). Being that these results are independent from the use of GP IIb-IIIa inhibitors, UFH should still remain the anticoagulation therapy of choice in ST-segment elevation myocardial infarction (STEMI) patients. Minimisation of bleeding complications by extensive use of the radial approach, in the setting of STEMI, may further contribute to the adoption of a more aggressive antithrombotic and antiplatelet therapy incorporating the use of GP IIb-IIIa inhibitors. The establishment of dedicated networks for STEMI, and the large STEMI campaign, will certainly contribute to increase the proportion of patients presenting at first medical contact within the early phase (3 h) of infarction and therefore highly suitable for a more aggressive pharmacoinvasive approach with upstream administration of GP IIb-IIIa inhibitors. In fact, although the current therapeutic targets of increased rates of timely reperfusion, mainly by primary percutaneous coronary intervention (PCI), has been achieved, a deep look into the future in the fight against MI will certainly put aborting infarction as the major desirable target to be achieved.
journal_name
Drugsjournal_title
Drugsauthors
De Luca G,Savonitto S,van't Hof AW,Suryapranata Hdoi
10.1007/s40265-015-0425-7subject
Has Abstractpub_date
2015-07-01 00:00:00pages
1229-53issue
11eissn
0012-6667issn
1179-1950journal_volume
75pub_type
杂志文章,评审相关文献
DRUGS文献大全abstract::Diabetes mellitus has become the most common single cause of end-stage renal disease in the Western world. Diabetic nephropathy, as most forms of renal disease leading to end-stage renal failure, is frequently complicated by arterial hypertension. In type 1 diabetes mellitus the reported excess in arterial hypertensio...
journal_title:Drugs
pub_type: 杂志文章,评审
doi:
更新日期:2003-01-01 00:00:00
abstract::Subcutaneous dulaglutide (Trulicity®) is a once-weekly glucagon-like peptide-1 receptor agonist that is approved in numerous countries as an adjunct to diet and exercise for the treatment of adults with type 2 diabetes (T2D). In the clinical trial and real-world settings, once-weekly subcutaneous dulaglutide, as monot...
journal_title:Drugs
pub_type: 杂志文章,评审
doi:10.1007/s40265-020-01260-9
更新日期:2020-02-01 00:00:00
abstract::Slowing of nerve conduction, a hallmark of both experimental and human diabetic neuropathy, is improved or corrected by aldose reductase inhibitors such as sorbinil. Animal experiments suggest that a myo-inositol-related defect in nerve sodium-potassium adenosine triphosphatase (ATPase) is responsible for the acute re...
journal_title:Drugs
pub_type: 杂志文章,评审
doi:10.2165/00003495-198600322-00004
更新日期:1986-01-01 00:00:00
abstract:BACKGROUND:The lowering of cholesterol concentrations in individuals at high risk of cardiovascular disease improves outcome. No study, however, has assessed benefits of cholesterol lowering in the primary prevention of coronary heart disease (CHD) in hypertensive patients who are not conventionally deemed dyslipidaemi...
journal_title:Drugs
pub_type: 临床试验,杂志文章,多中心研究,随机对照试验
doi:10.2165/00003495-200464002-00005
更新日期:2004-01-01 00:00:00
abstract::Oral abiraterone acetate, in combination with prednisone/prednisolone, is used to treat patients with metastatic castration-resistant prostate cancer (CRPC) who have previously received docetaxel-containing chemotherapy. Abiraterone acetate was developed to specifically inhibit cytochrome P450 (CYP)17A1, which is an e...
journal_title:Drugs
pub_type: 杂志文章
doi:10.2165/11208080-000000000-00000
更新日期:2011-10-22 00:00:00
abstract::Inhaled mometasone furoate (Asmanex) is a synthetic corticosteroid indicated for the first-line maintenance prophylactic therapy of persistent asthma in adults and adolescents. It is formulated for delivery via a breath-actuated dry powder inhaler (DPI) [Twisthaler].Inhaled mometasone furoate delivered by DPI is effec...
journal_title:Drugs
pub_type: 杂志文章,评审
doi:10.2165/00003495-200666080-00011
更新日期:2006-01-01 00:00:00
abstract::In a double-blind, parallel-group randomised trial of 3 months' duration, the efficacy of cyclandelate 800 mg twice daily in migraine prophylaxis was compared with that of flunarizine 5mg daily in 40 patients. In comparison with placebo and baseline values, both drugs significantly relieved symptoms of migraine as ass...
journal_title:Drugs
pub_type: 临床试验,杂志文章,随机对照试验
doi:10.2165/00003495-198700332-00019
更新日期:1987-01-01 00:00:00
abstract::Oxatomide is an orally active H1-histamine receptor antagonist which, as appears to occur with some other antihistamines, also inhibits mast cell degranulation. Oxatomide has demonstrated response rates similar to those with other more established members of its drug class in a few studies of chronic urticaria and all...
journal_title:Drugs
pub_type: 杂志文章,评审
doi:10.2165/00003495-198427030-00003
更新日期:1984-03-01 00:00:00
abstract::Alfuzosin, a new quinazoline derivative, acts as a selective and competitive antagonist of alpha 1-adrenoceptor-mediated contraction of prostatic, prostatic capsule, bladder base and proximal urethral smooth muscle, thereby reducing the tone of these structures. Consequently, urethral pressure and resistance, bladder ...
journal_title:Drugs
pub_type: 杂志文章,评审
doi:10.2165/00003495-199345030-00008
更新日期:1993-03-01 00:00:00
abstract:UNLABELLED:The aminosalicylate balsalazide is a prodrug which is metabolised by bacterial azo reductases in the colon to release its therapeutically active moiety mesalazine [mesalamine (US) or 5-aminosalicylic acid] and an inert carrier molecule. The systemic absorption of balsalazide and its metabolites is not requir...
journal_title:Drugs
pub_type: 杂志文章,评审
doi:10.2165/00003495-200262110-00010
更新日期:2002-01-01 00:00:00
abstract::A number of new agents for the management of chronic obstructive pulmonary disease (COPD) are at different stages of development, including several inhaled long-acting antimuscarinics (LAMA). Long-acting bronchodilators are considered to be central to the management of COPD due to the evidence supporting their efficac...
journal_title:Drugs
pub_type: 杂志文章,meta分析,评审
doi:10.1007/s40265-015-0532-5
更新日期:2016-03-01 00:00:00
abstract::Infliximab, the chimeric monoclonal antibody directed against tumour necrosis factor (TNF)-alpha, has profoundly changed therapy for Crohn's disease (CD). However, for ulcerative colitis (UC), before the publication of ACT 1 and ACT 2 (Active Ulcerative Colitis Trials 1 and 2), there were only a few open-label and con...
journal_title:Drugs
pub_type: 杂志文章,评审
doi:10.2165/00003495-200666160-00002
更新日期:2006-01-01 00:00:00
abstract::Alteplase is the product of recombinant DNA technology and is chemically identical to endogenous tissue-type plasminogen activator: Plasminogen is converted to plasmin by alteplase, and fibrinolysis of blood thrombi is subsequently stimulated. Alteplase is now firmly established as a treatment of choice in the managem...
journal_title:Drugs
pub_type: 杂志文章,评审
doi:10.2165/00003495-199550020-00007
更新日期:1995-08-01 00:00:00
abstract::Anagrelide (Agrylin, Xagrid) is an oral imidazoquinazoline agent which is indicated in Europe for the reduction of elevated platelet counts in at-risk patients with essential thrombocythaemia who are intolerant of or refractory to their current therapy, and in the US for the reduction of elevated platelet counts and t...
journal_title:Drugs
pub_type: 杂志文章,评审
doi:10.2165/00003495-200666010-00006
更新日期:2006-01-01 00:00:00
abstract::Antibacterial activities of cefotaxime and its major metabolite, desacetylcefotaxime, against 178 strains (of 10 species) were assessed in terms of minimum inhibitory concentrations (MIC50 and MIC80), and were compared with those of cefoperazone and ceftazidime. The activity of desacetylcefotaxime was several times le...
journal_title:Drugs
pub_type: 杂志文章
doi:10.2165/00003495-198800352-00013
更新日期:1988-01-01 00:00:00
abstract::Nateglinide is a novel D-phenylalanine derivative that inhibits ATP-sensitive K+ channels in pancreatic beta-cells in the presence of glucose and thereby stimulates the prandial release of insulin. Nateglinide reduces fasting and mealtime blood glucose levels in animals, healthy volunteers, and patients with type 2 (n...
journal_title:Drugs
pub_type: 杂志文章,评审
doi:10.2165/00003495-200060030-00007
更新日期:2000-09-01 00:00:00
abstract::In a double-blind study, the efficacy and tolerability of nimesulide (100mg twice daily) were compared with those of diclofenac (50mg twice daily) when administered orally to 50 patients with acute superficial thrombophlebitis of the lower limbs. Pain relief and amelioration of inflammation were apparent in patients t...
journal_title:Drugs
pub_type: 临床试验,杂志文章,随机对照试验
doi:10.2165/00003495-199300461-00050
更新日期:1993-01-01 00:00:00
abstract::Pinacidil is a newly developed antihypertensive vasodilator, proposed to belong to the new group of smooth muscle relaxants, the K+ channel openers. The in vitro effects of pinacidil on induced tone, smooth muscle membrane potential and 86Rb and 42K efflux from rat resistance vessels (internal diameter about 200 micro...
journal_title:Drugs
pub_type: 杂志文章
doi:10.2165/00003495-198800367-00006
更新日期:1988-01-01 00:00:00
abstract::Quinupristin-dalfopristin (RP 59500) is an injectable streptogramin antibiotic. It possesses a wide spectrum of activity against Gram-positive bacteria including methicillin-resistant staphylococci, glycopeptide-resistant. Enterococcus faecium and penicillin-resistant pneumococci. Quinupristin-dalfopristin has activit...
journal_title:Drugs
pub_type: 杂志文章,评审
doi:10.2165/00003495-199652030-00006
更新日期:1996-09-01 00:00:00
abstract::The popularity of antidepressants in the treatment of insomnia is not supported by a large amount of convincing data, but rather by opinions and beliefs of the prescribing physicians on the advantages of these agents compared with drugs acting on the benzodiazepine receptor or other drugs used for the treatment of ins...
journal_title:Drugs
pub_type: 杂志文章
doi:10.2165/0003495-200868170-00001
更新日期:2008-01-01 00:00:00
abstract::Ascletis has developed danoprevir (Ganovo®), an orally-administered hepatitis C virus NS3 protease inhibitor, as a treatment for hepatitis C. Based on positive results in phase II and phase III trials in patients with hepatitis C, danoprevir, in combination with ritonavir, peginterferon alfa and ribavirin was recently...
journal_title:Drugs
pub_type: 杂志文章,评审
doi:10.1007/s40265-018-0960-0
更新日期:2018-08-01 00:00:00
abstract::Methotrexate has been approved for the treatment of refractory rheumatoid arthritis by several regulatory agencies, including the Food and Drug Administration. The tendency is now to prescribe it at earlier stages of the disease. Methotrexate is a well known antifolate. Its exact mechanism of action in rheumatoid arth...
journal_title:Drugs
pub_type: 杂志文章,评审
doi:10.2165/00003495-199447010-00003
更新日期:1994-01-01 00:00:00
abstract::Azimilide is a potassium channel antagonist that, in contrast to existing class III antiarrhythmic agents, blocks both the rapidly (I(Kr)) and slowly (I(Ks)) activating components of the delayed rectifier potassium current. In animal and clinical studies, azimilide prolonged repolarisation by increasing the action pot...
journal_title:Drugs
pub_type: 杂志文章
doi:10.2165/00003495-200059020-00016
更新日期:2000-02-01 00:00:00
abstract::Cardiovascular diseases are the leading cause of mortality in industrialized countries. Treatment with statins is effective in primary prevention in patients at high cardiovascular risk. Statins are inhibitors of hydroxymethylglutaryl-coenzyme A (HMG-CoA) reductase and are classed as lipid-lowering drugs. In 2010, ato...
journal_title:Drugs
pub_type: 杂志文章,评审
doi:10.2165/11632010-000000000-00000
更新日期:2012-04-16 00:00:00
abstract::Schistosomiasis, a grave and debilitating disease of socioeconomic importance, is increasing in incidence despite concerted efforts to control and contain the disease in all the endemic areas. While a multipronged method of control using health education, sanitation and snail control has been used, chemotherapy and ch...
journal_title:Drugs
pub_type: 杂志文章,评审
doi:10.2165/00003495-199142030-00004
更新日期:1991-09-01 00:00:00
abstract::A rapid, practical diagnostic scheme is the key to selecting proper candidates for treatment with bromocriptine. The evaluation centres around assays for prolactin and follicle stimulating hormone, polytomography and computerised axial tomography of the sella turcica and parasellar regions, and the ergot alkaloid, bro...
journal_title:Drugs
pub_type: 杂志文章,评审
doi:10.2165/00003495-197917050-00004
更新日期:1979-05-01 00:00:00
abstract:UNLABELLED:Oral delayed-release mesalazine is an enteric-coated formulation which releases mesalazine in the terminal ileum and colon. Up to 74% of patients with mild to moderately active ulcerative colitis experience endoscopic or symptomatic improvement (including remission) or both when treated with oral delayed-rel...
journal_title:Drugs
pub_type: 杂志文章,评审
doi:10.2165/00003495-199957030-00013
更新日期:1999-03-01 00:00:00
abstract::Because platelets are so important in thrombus formation, drugs which inhibit platelet function (the 'antiplatelet drugs') have considerable potential as antithrombotic agents. Among the antiplatelet drugs, only aspirin, sulphinpyrazone, dipyridamole, hydroxychloroquine, and clofibrate have had wide clinical trial. Th...
journal_title:Drugs
pub_type: 杂志文章,评审
doi:10.2165/00003495-197918060-00002
更新日期:1979-12-01 00:00:00
abstract::It is important to distinguish between therapy used to reduce acute inflammation in gout and therapy used to manage hyperuricaemia in patients with chronic gouty arthritis. This article discusses treatments for acute gout, emphasizing the use of corticotrophin (adrenocorticotropic hormone; ACTH) and the evidence on wh...
journal_title:Drugs
pub_type: 杂志文章,评审
doi:10.2165/00003495-200868040-00002
更新日期:2008-01-01 00:00:00
abstract::25 years have elapsed since the introduction of the first effective oral diuretic, chlorothiazide. Diuretics are now amongst the most widely prescribed drugs in clinical practice worldwide. Availability of these drugs has not only brought therapeutic benefit to countless numbers of patients but it has at the same time...
journal_title:Drugs
pub_type: 杂志文章,评审
doi:10.2165/00003495-198529020-00003
更新日期:1985-02-01 00:00:00